Domínguez, Juan Manuel
Pérez-Chacón, Gema
Guillén, María José
Muñoz-Alonso, María José
Somovilla-Crespo, Beatriz
Cibrián, Danay
Acosta-Iborra, Bárbara
Adrados, Magdalena
Muñoz-Calleja, Cecilia
Cuevas, Carmen
Sánchez-Madrid, Francisco
Avilés, Pablo
Zapata, Juan M.
Funding for this research was provided by:
Ministerio de Economía y Competitividad (MINECO) and European Regional Development’s funds (IPT-2012-0198-090000, IPT-2012-0198-090000, IPT-2012-0198-090000)
Consejo Superior de Investigaciones Científicas (2019AEP146)
Article History
Received: 8 November 2019
Accepted: 27 March 2020
First Online: 7 April 2020
Ethical approval and consent to participate
: Human samples were from patients enrolled in the ET-B-027-06 phase II clinical trial sponsored by PharmaMar (EudraCT Number: 2007-000794-31) and archived pathology samples from Hospital Universitario de la Princesa. The clinical study was performed in accordance with the principles of the Declaration of Helsinki and was approved and supervised by the IRB of US Oncology Inc and by the Ethics Committee of Hospital Universitario de la Princesa (CEI 3989). Written informed consent was obtained from each patient before they entered the study. All animal protocols were reviewed and approved according to regional Institutional Animal Care and Use Committees.
: Not applicable
: JMD, PA, MJG, MJM-A, and CC are employees and/or shareholders of PharmaMar. The rest of authors (GP-C, BS-M, DC, BA-I, MA, CM-C, FS-M, and JMZ) declare that they have no competing interest.